Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma: A pilot study of the BOMES protocol

Cancer

Volumn 82, Issue 10, 1998, Pages 1946-1951

  Cheng, Ann Lii ^a,b   Yeh, Kun Huei ^a,b   Uen, Wu Ching ^a   Hung, Ruey Long ^a,b   Liu, Mei Ying ^a,b   Wang, Chiu Hwa ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Central nervous system; Chemotherapy; Disease free survival; Lymphoma; Remission

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; VINCRISTINE;

ADULT; AGED; ARTICLE; BRAIN LYMPHOMA; BRAIN RADIATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; FEMALE; HEPATITIS; HUMAN; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; SEPSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE PROGRESSION; ETOPOSIDE; FEMALE; HUMANS; LYMPHOMA, AIDS-RELATED; MALE; METHOTREXATE; METHYLPREDNISOLONE HEMISUCCINATE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE;

EID: 0032525224     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980515)82:10<1946::AID-CNCR19>3.0.CO;2-T     Document Type: Article

References (24)

1. Fine HA. Treatment of primary central nervous system lymphoma: still more questions than answers. Blood 1995;86:2873-5.
2. Mackintosh FR, Colby TV, Podolsky WJ, Burke JS, Hoppe RT, Rosenfelt FP, et al. Central nervous system involvement in non-Hodgkin's lymphoma: an analysis of 105 cases. Cancer 1982;49:586-95.
3. Lachance DH, Brizel DM, Gockerman JP, Halperin EC, Burger PC, Boyko OB, et al. Cyclophosphamide, doxorubicin, vincristine, and prednisolone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy. Neurology 1994;44:1721-7.
4. O'Neill BP, O'Fallon JR, Earle JD, Colgan JP, Brown LD, Krigel RL. Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy? Int J Radiat Oncol Biol Phys 1995;33:663-73.
5. Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD, et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by radiation therapy oncology group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 1992;23:9-17.
6. DeAngelis LM, Yahalom I, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J Clin Oncol 1992;10:635-43.
7. Glass I, Gruber ML, Cher L, Hochberg FH. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 1994;81: 188-95.
8. Blay JY, Carrie C, Bouffet E, Brunat-Mentigny M, Philip T, Biron P. The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression. Blood 1995;86:2922-9.
9. Neuwelt EA, Goldman DL, Dahlborg SA, Crosse J, Ramsey F, Roman-Goldstein S, et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 1991;9:1580-90.
10. McLaughlin P, Velasquez WS, Redman JR, Yung WKA, Hagemeister FB, Rodriguez MA, et al. Chemotherapy with dexamethasone, high-dose cytarabine, and cisplatin for parenchymal brain lymphoma. J Natl Cancer Inst 1988;80: 1408-12.
11. Gabbai AA, Hochberg FH, Linggood RM, Bashir R, Hotleman K. High-dose methotrexate for non-AIDS primary central nervous system lymphoma. J Neurosurg 1989;70:190-4.
12. Cohen IJ, Vogel R, Matz S, Weitz R, Mor C, Stern S, et al. Successful non-neurotoxic therapy (without radiation) of a multifocal primary brain lymphoma with a methotrexate, vincristine, and BCNU protocol (DEMOB). Cancer 1986; 57:6-11.
13. Freilich B, Delattre JY, Monjour A, DeAngelis LM. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 1996;46:435-9.
14. Kaplan EJ, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
15. Yeh KH, Cheng AL, Tien HF. Primary T-cell leptomeningeal lymphoma - successful treatment with systemic chemotherapy. Oncology 1995;52:501-4.
16. Grant JW, Isaacson PG. Primary central nervous systemic lymphoma. Brain Pathol 1992;2:97-109.
17. Fine HA, Mayer RJ. Primary central nervous system lymphoma. Ann Intern Med 1993;119:1093-104.
18. Beral V, Peterman T, Berkelman R, Jaffe H. AIDS-associated non-Hodgkin's lymphoma. Lancet 1991;337:805-9.
19. Eby NL, Grufferman S, Flannelly CM, Schold C, Vogel S, Burger PC. Increasing incidence of primary brain lymphoma in the us. Cancer 1988;62:2461-5.
20. Litam JP, Cabanillas F, Smith TL, Bodey GP, Freireich EJ. Central nervous system relapse in malignant lymphoma: risk factors and implication of prophylaxis. Blood 1979;54:1249-57.
21. Henry JM, Hoffner RR, Dillard SH, Earle KM, Davis RL. Primary lymphoma of the central nervous system. Cancer 1974;34:1293-302.
22. Berry MP, Simpson WJ. Radiation therapy in the management of primary malignant lymphoma of the brain. Int J Radiat Oncol Biol Phys 1981;7:55-9.
23. Wolff SN. High-dose therapy for brain tumors: rationale, results, and revelations. In: Armitage JO, Antman KH, editors. High-dose cancer therapy: pharmacology, hematopoietins, stem cells. Baltimore: Williams and Wilkins, 1992:755-71.
24. Cheng AL. Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma. Blood 1996;87:1202.